Associated Genetic Biomarkers
Cyclin-dependent kinase inhibitor 2B (CDKN2B, also known as p15) is a gene that encodes a protein that binds to CDK4 or CDK6 and inhibits their activation. Missense and silent mutations are observed in cancers such as intestinal cancer, kidney cancer, and cancers of the urinary tract.
CDKN2B is altered in 6.54% of all cancers with conventional glioblastoma multiforme, lung adenocarcinoma, bladder urothelial carcinoma, glioblastoma, and pancreatic adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CDKN2B are CDKN2B Loss (7.27%), CDKN2B Mutation (0.27%), CDKN2B Amplification (0.07%), CDKN2B A70V (0.01%), and CDKN2B E121K (0.01%) .
CDKN2B status serves as an inclusion eligibility criteria in 7 clinical trials, of which 6 are open and 1 is closed. Of the trials that contain CDKN2B status as an inclusion criterion, 4 are early phase 1 (4 open) and 3 are phase 2 (2 open).
Trials with CDKN2B status in the inclusion eligibility criteria most commonly target glioblastoma, malignant glioma, and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CDKN2B Loss .
Abemaciclib, ly3214996, bevacizumab, ceralasertib, and everolimus are the most frequent therapies in trials with CDKN2B as an inclusion criteria .
Significance of CDKN2B in Diseases
CDKN2B is altered in 36.67% of glioblastoma patients .
CDKN2B is an inclusion criterion in 3 clinical trials for glioblastoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2B status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (1 open) .
Malignant Glioma +
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.